Jean Nappi to Clinical Trials as Topic
This is a "connection" page, showing publications Jean Nappi has written about Clinical Trials as Topic.
Connection Strength
0.162
-
The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist. Clin Ther. 2003 Nov; 25(11):2647-68.
Score: 0.041
-
Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother. 2003 Jul-Aug; 37(7-8):1055-62.
Score: 0.040
-
Vitamins for the management of cardiovascular disease: a simple solution to a complex problem? Pharmacotherapy. 1999 Dec; 19(12):1400-14.
Score: 0.031
-
Sotalol: a breakthrough antiarrhythmic? Ann Pharmacother. 1993 Nov; 27(11):1359-68.
Score: 0.020
-
Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome. Ann Pharmacother. 2003 Jun; 37(6):860-75.
Score: 0.010
-
Efficacy of intravenous pirmenol hydrochloride for treatment of ventricular arrhythmias: a controlled comparison with lidocaine. J Cardiovasc Pharmacol. 1983 Mar-Apr; 5(2):213-20.
Score: 0.010
-
Sustained-release diltiazem: duration of antihypertensive effect. J Clin Pharmacol. 1989 Jun; 29(6):533-7.
Score: 0.004
-
Metabolic effects of antihypertensive therapy with a calcium antagonist. Am J Cardiol. 1988 Oct 05; 62(11):109G-113G.
Score: 0.004
-
Flecainide: a new prototype antiarrhythmic agent. Pharmacotherapy. 1985 Jul-Aug; 5(4):209-21.
Score: 0.003